Polysubstance use means being exposed to more than one drug at the same time or within a short period, whether or not you know it’s happening. The CDC defines it broadly: any situation where more than one substance is affecting your body at once. That includes someone who drinks alcohol and takes a prescription sedative, someone who intentionally combines stimulants and opioids, and someone who buys what they think is one drug but unknowingly gets a mixture laced with fentanyl or other additives.
The distinction between intentional and unintentional polysubstance use is critical, because the risks are high in both cases and the current drug supply makes unintentional exposure increasingly common.
Why Combining Substances Is More Dangerous Than Using One
When two or more drugs enter your body at the same time, they don’t simply stack their effects. Depending on the combination, they can interact in ways that are additive, synergistic, or antagonistic. Additive means the combined effect roughly equals the sum of each drug’s individual effect. Synergistic means the combination produces a stronger effect than you’d expect from adding the two together. Antagonistic means one drug partially blocks the effect of another.
Synergistic interactions are especially dangerous because they can catch people off guard. Drinking alcohol before using cannabis, for example, raises the active compound levels in your blood and intensifies the high beyond what either substance would produce alone. Combining cocaine and nicotine floods the brain’s reward system with far more of the “feel-good” chemical dopamine than either drug triggers on its own. And when alcohol is combined with nicotine over time, the cellular damage is compounded: lab studies show the combination triggers roughly 2.5 times more cell death signaling than either substance alone.
The most life-threatening synergy involves respiratory depression. Alcohol, opioids, and sedatives like benzodiazepines each slow breathing through different pathways in the brainstem. When combined, these effects stack on top of each other, and the result can be fatal. Your brain simply stops sending adequate signals to breathe. This is the mechanism behind most polysubstance overdose deaths.
The Most Common Drug Combinations
The combinations showing up most frequently in overdose data have shifted dramatically over the past decade. The fraction of U.S. overdose deaths involving both fentanyl and stimulants surged from 0.6% in 2010 to 32.3% in 2021. By 2023, the most common cluster found in overdose deaths was methamphetamine, cocaine, and fentanyl together.
Methamphetamine and fentanyl are frequently used intentionally in combination, often purchased separately. But other combinations happen without the person’s knowledge. A drug product sold as fentanyl alone might actually contain fentanyl plus xylazine (a veterinary sedative), lidocaine, and other fillers. In rarer but higher-risk scenarios, something sold as a stimulant turns out to contain fentanyl or other potent synthetic opioids.
Alcohol remains one of the most common substances in polysubstance combinations, partly because people don’t always think of it as a “drug” they’re mixing with other substances. The well-established risk: combining alcohol with opioids or benzodiazepines is one of the most reliably fatal pairings.
The Growing Role of Adulterants
Unintentional polysubstance use is being driven by an increasingly unpredictable drug supply. Xylazine is a prime example. It’s a non-opioid sedative intended for veterinary use that has been showing up in illicitly manufactured fentanyl at alarming rates. Across 21 U.S. jurisdictions, the percentage of fentanyl-involved deaths where xylazine was also detected rose 276%, from 2.9% in January 2019 to 10.9% by June 2022. By 2022, the Drug Enforcement Administration reported that 23% of seized fentanyl powder and 7% of seized fentanyl pills contained xylazine.
What makes xylazine particularly dangerous is that naloxone (the standard opioid overdose reversal medication) doesn’t work on it. Someone overdosing on a fentanyl-xylazine combination may not respond fully to the emergency treatments bystanders and paramedics rely on. Beyond xylazine, the current drug supply increasingly contains novel synthetic benzodiazepines, synthetic cannabinoids, and other substances that make each exposure unpredictable.
Long-Term Health Consequences
Using multiple substances doesn’t just multiply the risk of overdose. It compounds the chronic damage to nearly every organ system. The cardiovascular effects are substantial: stimulants like cocaine directly raise blood pressure, and long-term alcohol use independently causes hypertension. Together, these effects accelerate the risk of heart attack and stroke. Methamphetamine, heroin, tobacco, and prescription stimulants all carry independent cardiovascular risks that worsen when layered on top of one another.
The liver takes a particularly heavy hit. Alcohol, opioids, methamphetamine, cocaine, and many prescription drugs are all independently toxic to liver tissue. Combining them forces the liver to process multiple toxic compounds simultaneously, increasing the risk of liver disease and, over time, cirrhosis.
Perhaps the most striking example of how combinations amplify harm comes from cancer risk. Tobacco use and heavy alcohol use each independently raise the risk of mouth and throat cancers, by roughly seven and six times respectively. But using both together raises the risk 38 times. That’s not additive math. It’s synergistic damage at the tissue level.
Chronic polysubstance use also damages the brain. Long-term alcohol use can cause a severe memory disorder called Wernicke-Korsakoff syndrome. Stimulants, opioids, sedatives, and even cannabis are all independently associated with increased dementia risk in older adults. Combining substances over years accelerates cognitive decline.
Who Is Most Affected
Polysubstance-involved overdoses are most common among adults ages 25 to 54, but they are not limited to that group. Research from Boston University and Mass General Brigham for Children found that among roughly 23,000 opioid overdose deaths in youth, polysubstance involvement increased steadily with age: 25% of opioid overdose deaths among 15-year-olds involved multiple substances, climbing to 40% among 18-year-olds, 53% among 21-year-olds, and 58% among 24-year-olds.
Stimulants were the most common additional substance in these youth deaths, present in about 12% of opioid deaths among 15-year-olds and 41% among 24-year-olds. These numbers reflect how early polysubstance patterns begin and how quickly they escalate during the transition from adolescence to young adulthood.
How Polysubstance Use Disorder Is Diagnosed
The current diagnostic manual (DSM-5-TR) doesn’t use a single “polysubstance use disorder” label the way its predecessor once did. Instead, clinicians diagnose a separate substance use disorder for each substance involved. So someone who has problems with both alcohol and opioids would receive two distinct diagnoses.
Each diagnosis is based on 11 possible criteria, grouped into four categories: loss of control over use (taking more than intended, failed attempts to stop, spending excessive time obtaining or recovering from the substance, and cravings), social impairment (failing to meet obligations, continued use despite relationship problems, giving up activities), risky use (using in dangerous situations, using despite known physical or psychological harm), and physical dependence (tolerance and withdrawal). Meeting 2 to 3 criteria qualifies as mild, 4 to 5 as moderate, and 6 or more as severe.
Having multiple substance use disorders simultaneously complicates every aspect of treatment. Withdrawal from several substances at once is difficult to manage safely outside a hospital setting. The behavioral approaches that work well for a single substance may need significant modification when someone is dependent on two or three. Treatment coordination becomes more complex, often requiring input from multiple specialists and outside agencies. The stigma surrounding drug use, already a barrier for single-substance treatment, intensifies when someone is dealing with multiple dependencies at once.